Martin Widschwendter and the project team outside the UCL Cancer Institute
UCL researchers have recently commenced an academic-industrial collaboration - EpiFemCare - to develop new methods for screening, diagnosing and personalising treatment of breast and ovarian cancers. The EpiFemCare project will develop blood tests that will enable new and improved means of cancer detection, as well as the evaluation of response to cancer treatment. This innovative, collaborative research project is led by Martin Widschwendter from the Department of Women's Cancer at the UCL EGA Institute for Women's Health. Collaborators include Charles University (Prague, Czech Republic), Ludwig Maximilians University (Munich, Germany), and companies with expertise in epigenetics and next generation screening (GATC Biotech, Germany) and managing the large volumes of data created by these experiments (Genedata, Switzerland). Project Coordinator, Professor Widschwendter, said: "Currently many women face an advanced ovarian cancer diagnosis or breast cancer over-diagnosis due to lack of suitable tests of early detection or over-zealous screening procedures. EpiFemCare scientists and clinicians are aspiring to change this through the development of blood based tests with increased sensitivity for ovarian cancers and increased specificity for breast cancers. The tests would also allow us to predict patient response to treatment, thereby personalising their treatment regimens".
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
